Specific genomic alterations in ERG and PTEN have been shown to have prognostic value in prostate cancer progression and recurrence. These tests include a proprietary analysis of the ERG gene by FISH, and in combination with PTEN, an overall prognostic assessment (favorable vs. poor)1 is provided to help inform the decision to proceed with either treatment or active surveillance.

Provides greater insight into the aggressiveness of prostate cancer in patients who fall into the traditionally “low and intermediate risk” category (Gleason score 6 and 7)2

Low QNS rate (2%) versus competitors (can be as high as 30%)

Cost-effective and available via the TC/PC virtual platform to Pathologists

Rapid turnaround time of 3-4 days

Recommended Use
Evidence

References

  1. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene. 2007;27(3):253-263.
  2. National Comprehensive Cancer Network. The NCCN Guidelines for Prostate Cancer (Version 4.2013). J Natl Compr Canc Net. 2013.
  3. AUA Prostate Cancer Clinical Guideline Update Panel. Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update. J Urol. 2007;177(6):2106-2131.